Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) Director Sells $31,410.00 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $6.98, for a total transaction of $31,410.00. Following the completion of the transaction, the director now directly owns 74,438 shares of the company’s stock, valued at approximately $519,577.24. The trade was a 5.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Health Catalyst Stock Down 0.1 %

Shares of NASDAQ HCAT opened at $7.08 on Monday. The company’s 50 day moving average price is $7.96 and its 200-day moving average price is $7.48. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst, Inc. has a 52-week low of $5.42 and a 52-week high of $11.41. The company has a market capitalization of $430.80 million, a P/E ratio of -5.24 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same quarter in the previous year, the firm earned ($0.22) EPS. Health Catalyst’s quarterly revenue was up 3.5% on a year-over-year basis. Equities analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Stephens increased their price target on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Evercore ISI increased their target price on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. JPMorgan Chase & Co. boosted their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Royal Bank of Canada raised their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and an average price target of $11.79.

Institutional Investors Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. increased its holdings in Health Catalyst by 6.9% in the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after purchasing an additional 1,907 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Health Catalyst by 9.1% in the 2nd quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock valued at $582,000 after acquiring an additional 7,589 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in shares of Health Catalyst by 276.3% during the 2nd quarter. Los Angeles Capital Management LLC now owns 213,693 shares of the company’s stock valued at $1,365,000 after acquiring an additional 156,908 shares during the period. Acadian Asset Management LLC lifted its position in shares of Health Catalyst by 1.3% during the 2nd quarter. Acadian Asset Management LLC now owns 734,257 shares of the company’s stock valued at $4,690,000 after acquiring an additional 9,697 shares during the period. Finally, ClariVest Asset Management LLC boosted its stake in Health Catalyst by 1.2% during the second quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock worth $1,825,000 after acquiring an additional 3,302 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.